The global indoleamine 2,3 dioxygenase 1 market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Indoleamine 2,3-dioxygenase 1 (IDO1) is the first and rate-limiting enzyme of tryptophan catabolism through the kynurenine pathway. It is an important molecule in the mechanisms of tolerance. Furthermore, its physiological function suppresses the potentially dangerous inflammatory processes in the body. The major factor driving the growth of the market is the increasing prevalence of cancer across the globe.
Moreover, IDO1 inhibitors are used alone or in combination with immunotherapy, chemotherapy, adoptive transfer, COX-2 inhibitors, membrane-associated PGE2 synthase inhibitors, competitive antagonists and PI3K inhibitors among others to improve the inhibition of local immunosuppression around tumor tissues as well as to enhance tumor eradication. Furthermore, the combination of IFN-? treatment with IDO1 inhibitors is a new cancer immunotherapeutic strategy to effectively enhance antitumor immunity and eliminate TRCs.
To Request a Sample of our Report on Indoleamine 2,3 Dioxygenase 1 Market: https://www.omrglobal.com/request-sample/indoleamine-2-3-dioxygenase-1-market
Some major players in the market include Bristol-Myers Squibb Company, and Merck KGaA, among others . The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in January 2021, IO Biotech announced that it has raised $155 million in a Series B financing round to fund the clinical development of immune-modulating IDO and PD-L1 cancer vaccines. The company showed that combining its IDO and PD-L1 vaccines with Opdivo triggered complete responses in 45% of stage 4 melanoma patients.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Bristol-Myers Squibb Company, and Merck KGaA, among others
(Get 15% Discount on Buying this Report)
A full Report of Indoleamine 2,3 Dioxygenase 1 Market is Available @ https://www.omrglobal.com/industry-reports/indoleamine-2-3-dioxygenase-1-market
Global Indoleamine 2,3 Dioxygenase 1 Market Report by Segment
By Type
- BMS-986205
- Dcellvax
- Epacadostat
- F-001287
- Galanal
- Others
By Application
- Alopecia
- Cervical Cancer
- Gastric Cancer
- Glioma
- Others
Global Indoleamine 2,3 Dioxygenase 1 Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
